Janwillem Naesens

Janwillem Naesens is Managing Partner of DROIA Ventures, an investor group specializing in early-stage oncology drug development companies. At DROIA, he focuses on early-stage investments and company developments. Janwillem currently serves on the board of directors of Cyteir Therapeutics, Highlight Therapeutics, Octimet Oncology, Convert Pharmaceuticals, NormOxys, Black Belt Therapeutics, and Frontier Medicines. Janwillem holds an MSc in engineering from the University of Leuven and an MBA from INSEAD, Fontainebleau.